



Practitioner's Docket No. 18438/09050 (01427/1)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Briggs et al.

Application No.: 10/773,019 Filed: February 5, 2004

Group No.: 1614 Examiner: Unknown

For: Treatment and Prevention of Obesity with Cox-2 Inhibitors or in Combination with

Weight-Loss Agents

Mail Stop DD Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. section 1.8(a)

I hereby certify that the attached correspondence comprising:

- 1. First Class Mail Certificate of Mailing for All (1 page)
- 2. Information Disclosure Statement Transmittal Letter (2 pages)
- 3. Information Disclosure Citation in an Application (2 pages)
- 4. References Enclosed (27 each)
- 5. Return postcard (1 page)

is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

Mail Stop DD
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

On August 9, 2004.

Terry P. Ballew

Signature of erson mailing paper

DOCKET NO: 18438/09050

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of Briggs et al.

Serial No: 10/773,019

Filed: February 5, 2004

Title: TREATMENT AND PREVENTION OF

OBESITY WITH COX-2 INHIBITORS OR IN COMBINATION WITH WEIGHT-LOSS

AGENTS

Examiner: Unknown

Art Unit: 1614

Deposit Account: 50-2548

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R 1.56, 1.97 and 1.98, Applicant is submitting the art shown on the attached list for consideration by the Examiner. By this submission, it is not admitted that any of the listed references are, in fact, prior art. The Examiner is respectfully requested to make an independent search and evaluation of all relevant prior art.

This Information Disclosure Statement is being filed prior to the mailing of a first office action on the merits and, therefore, no additional filing fee or certification is required.

The Examiner is encouraged to contact the undersigned at his convenience should there be any questions regarding this matter or require any additional information.

Respectfully requested,

NELSON MULLINS RILEY & SCARBOROUGH

August 9, 2004. Date

Robert S. Thomas Registration No. 52,284

1320 Main Street / 17th Floor

Columbia, SC 29201 Phone: (864) 250-2298

Fax: (803) 256-7500

I hereby certify that this paper, all attachments, and any fees are being deposited with the U.S. Postal Service as "First Class Mail" and is addressed: Mail Stop DD, Commissioner for Patents, P.O Box 1450, Alexandria, VA 22313-1450 on August 9, 2004.

(Name and signature of person mailing paper or fee)

IF.

Docket Marcher Optional 18438/0905 Form PTO-1449 **Application Number** 10/773,019 **Applicant** Filing Date INFORMATION DISCLOSURE CITATION Briggs et al. February 5, 2004 IN AN APPLICATION Examiner Group Art Unit (Use several sheets if necessary) Unknown 1614 **U.S. PATENT DOCUMENTS EXAMINER** FILING DATE SUBCLASS DOCUMENT NUMBER CLASS DATE NAME INITIAL IF APPROPRIATE 11/05/2002 5 5 3 0 Kuhrts 424 725 6 2 0 0 9 9 5 03/13/2001 De la Brouse-Elwood et al. 514 347 03/07/2000 3 6 0 3 6 5 6 Mikami et al. 424 78.3 **FOREIGN PATENT DOCUMENTS** Translation DOCUMENT NUMBER DATE CLASS SUBCLASS NAME YES OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) U.S. Patent Publication 2002/0132773, Published September 19, 2002, Methods for Reducing Fat by Administration of Adiponectin Article by Altiok et al., Genes & Development 11:1987-1998, pp. 1987-1998, entitled PPARY Induces Cell Cycle Withdrawal: Inhibition of E2F / DP DNA-binding Activity Via Down-Regulation of Abstract by P. Arner from Int J Obes Relat Metab Disord 1993; 17 Suppl 1:S57-9, entitled Adenosine, Prostaglandins and Phosphodiesterase as Targets for Obesity Pharmacotherapy Article by R.P. Brun et al. from Journal of Endocrinology (1997) 155, 217-218, entitled Obesity and the Adipocyte; PPARY and the Molecular Control of Adipogenesis. Abstract by Chawla, et al. from Endocrinology 1994 Aug; 135(2):798-800, entitled Peroxisome Proliferator-Activated Receptor (PPAR) Gamma: Adipose-Predominant Expression and Induction Early in Adipocyte Differentiation. Abstract by Coya et al. from Biology of Reproduction—Abstracts: Coya et al. 65 (3): 814, entitled Effect of Cyclic 3', 5'-Adenosine Monophosphate, Glucocorticoids, and Insulin on Leptin Messenger RNA Levels and Leptin Secretion in Cultured Human Trophoblast. Abstract by DuBois et al. from Carcinogenesis 1998 Jan; 19(1):49-53, entitled The Nuclear Eicosanoid Receptor, PPARgamma, is Aberrantly Expressed in Colonic Cancers. Abstract by Dulloo et al. from Metabolism 1992 Nov; 41(11):1233-41, entitled Potentiation of the Thermogenic Antiobesity Effects of Ephedrine by Dietary Methylxanthines: Adenosine Antagonism or Phosphodiesterase Inhibition? Article by Fain, et al. from Journal of Lipid Research, Volume 41,2000, pgs. 1689-1694, entitled Eicosanoids as Endogenous Regulators of Leptin Release and Lipolysis by Mouse Adipose Tissue in Primary Culture. Abstract by Fajas et al. from Dev Cell 2002 Jul; 3(1):39-49, entitled E2Fs Regulate Adipocyte Differentiation. Abstract by Gerhold et al. from Endocrinology 2002 Jun; 143(6):2106-18, entitled Gene Expression Profile of Adipocyte Differentiation and its Regulation by Peroxisome Proliferator-activated Receptor-gamma Agonists. Article by Gregoire et al. from Physiological Reviews, Vol. 78, No. 3, July 1998, entitled Understanding Adipocyte Differentiation. Article by Halaas et al. from Journal of Endocrinology (1997) 155, 215-216, entitled Obesity and the Adipocyte; Leptin and its Receptor. Article by Kim et al. from J. Nutr. 130: 3110S-3115S, 2000, entitled Symposium: Adipocyte Function, Differentiation and Metabolism; Secretory, Endocrine and Autocrine/Paracrine Function of the Adipocyte¹. Abstract by Kliewer et al. from Cell 1995 Dec 1;83(5):813-9, entitled A Prostaglandin J2 Metabolite Binds Peroxisome Proliferator-Activated Receptor Gamma and Promotes Adipocyte Differentiation.

		ĭ/	
Form PTO-1449	Docket Number Intional 18438/09050	Application Number 10/773,019	
INFORMATION DISCLOSURE CITATION	Applicant	Filing Date	
IN AN APPLICATION	Briggs et al.	February 5, 2004	
(Use several sheets if necessary)	Examiner Unknown	Group Art Unit 1614	
Article by Kulkarni et al. from Method Vol. 22, No. 5, 2000, pp. 291-298, en Potential for Selective COX-2 Inhibito	titled Cyclooxygenase Isoena		
Article by Lee et al. from American Pl Abnormalities in Macrophages from L			
Article by Mokdad et al. from The Jou September 2001, pp 1195-1200, entil United States [Original Contribution].			
Article by Reusch et al. from Molecular and Cellular Biology, Feb. 2000, p. 1008-1020, Vol. 20, No. 3, entitled CREB Activation Induces Adipogenesis in 3T3-L1 Cells.			
Abstract by Rondinone et al. from En		6):2421-6, entitled Aldosterone	
Through PPARY: a Unified Pathway.	Article by Rosen et al. from Genes & Development 16:22-26, entitled C/EBPα Induces Adipogenesis Through PPARy: a Unified Pathway.		
Article by Rosen et al. by Annu. Rev. of Adipogenesis.	Cell Dev. Biol. 2000, 16:145-	71, entitled Molecular Regulation	
	Article by Rosen et al. from Genes & Development 14:1293-1307, pp. 1293-1307, entitled Transcriptional Regulation of Adipogenesis.		
Article by Ross et al. from Science Ma Inhibition of Adipogenesis by Wnt Sig	agazine, Vol. 289, 11 August	2000, pp. 950-953, entitled	
Article by Snyder from Emerging The cGMP-Inhibited Cyclic Nucleotide Photogenic Agents for the Treatment	osphodiesterase (PDE3B) as nt of Obesity.	a Target for Lipolytic and	
Abstract by Das from Nutrition, November 1, 2001; 17(11-12): 953-66, entitled Is Obesity an Inflammatory Condition?			
Article by Wangsness from Minnesota Medical Association, November 2000, Vol. 83, entitled Pharmacological Treatment of Obesity: Past, Present, and Future.			
Article by Yokota et al. from The Jour 1303-1310, entitled Paracrine Regula Adiponectin and Prostaglandins.			
EXAMINER	DATE CONSIDERED	· · · · · · · · · · · · · · · · · · ·	

2

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.